Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Eytelia is a Belgian biotechnology company specializing in the development and manufacturing of bio-activated organic silicon-based products for human health. The company leverages its proprietary monomethylsilanetriol (MMST) technology to create highly bioavailable solutions targeting joint health, bone density, and skin rejuvenation. Eytelia operates as a vertically integrated entity, managing research, development, and large-scale production of its proprietary molecules. Their product portfolio includes both finished consumer brands and raw materials for the pharmaceutical and nutraceutical industries. The company's core expertise lies in the stabilization of organic silicon to ensure optimal absorption and efficacy in the human body. Eytelia serves a global market, providing innovative solutions for musculoskeletal disorders and anti-aging applications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Eytelia.